| scholarly article | Q13442814 |
| P50 | author | Omid C. Farokhzad | Q40380290 |
| Bruce R Zetter | Q116547864 | ||
| P2093 | author name string | Jun Wu | |
| Alexander R Votruba | |||
| Xiaoyang Xu | |||
| Jinjun Shi | |||
| Xi Zhu | |||
| Eric Pridgen | |||
| Yingjie Xu | |||
| Archana Swami | |||
| P2860 | cites work | Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles | Q29615957 |
| Rescue of paclitaxel sensitivity by repression of Prohibitin1 in drug-resistant cancer cells | Q33664289 | ||
| Prohibitins Are Required for Cancer Cell Proliferation and Adhesion | Q33697928 | ||
| Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. | Q34227677 | ||
| First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement | Q34324970 | ||
| Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance | Q35924301 | ||
| The role and therapeutic potential of prohibitin in disease | Q36018450 | ||
| Current progress of siRNA/shRNA therapeutics in clinical trials | Q36071638 | ||
| Differentially charged hollow core/shell lipid-polymer-lipid hybrid nanoparticles for small interfering RNA delivery. | Q36448811 | ||
| Nanomedicine: developing smarter therapeutic and diagnostic modalities | Q36637207 | ||
| Targeted polymeric therapeutic nanoparticles: design, development and clinical translation | Q36934007 | ||
| Knocking down barriers: advances in siRNA delivery | Q37380671 | ||
| RNA interference in the clinic: challenges and future directions | Q37821230 | ||
| Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation. | Q37892517 | ||
| Nanoparticle-based combination therapy toward overcoming drug resistance in cancer | Q37979618 | ||
| Gelatin nanospheres incorporating siRNA for controlled intracellular release | Q39276991 | ||
| Tailoring nanostructured solid-lipid carriers for time-controlled intracellular siRNA kinetics to sustain RNAi-mediated chemosensitization | Q39607730 | ||
| Sustained local delivery of siRNA from an injectable scaffold | Q39641314 | ||
| Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. | Q54541283 | ||
| Localized, targeted, and sustained siRNA delivery | Q83460693 | ||
| P433 | issue | 5 | |
| P921 | main subject | nanoparticle | Q61231 |
| gene silencing | Q1431332 | ||
| P304 | page(s) | 897-900 | |
| P577 | publication date | 2014-03-17 | |
| P1433 | published in | Nanomedicine: Nanotechnology, Biology and Medicine | Q6964073 |
| P1476 | title | Hybrid lipid-polymer nanoparticles for sustained siRNA delivery and gene silencing | |
| P478 | volume | 10 |
| Q37581374 | Accelerating the Translation of Nanomaterials in Biomedicine |
| Q36271488 | Biomaterials for mRNA delivery |
| Q50854702 | Controlling Release of Integral Lipid Nanoparticles Based on Osmotic Pump Technology. |
| Q98224914 | Innovative Therapeutic and Delivery Approaches Using Nanotechnology to Correct Splicing Defects Underlying Disease |
| Q36957575 | Intracellular trafficking and exocytosis of a multi-component siRNA nanocomplex |
| Q38556750 | Lipid-coated polymeric nanoparticles for cancer drug delivery |
| Q64076280 | Lipid-polymer hybrid nanoparticles as a next-generation drug delivery platform: state of the art, emerging technologies, and perspectives |
| Q35796255 | Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment. |
| Q38777279 | Lysozyme-loaded lipid-polymer hybrid nanoparticles: preparation, characterization and colloidal stability evaluation. |
| Q34245494 | Nanomedicine in the Management of Microbial Infection - Overview and Perspectives |
| Q36644318 | Polydopamine-Based Surface Modification of Novel Nanoparticle-Aptamer Bioconjugates for In Vivo Breast Cancer Targeting and Enhanced Therapeutic Effects. |
| Q37736085 | Quantum Dots-siRNA Nanoplexes for Gene Silencing in Central Nervous System Tumor Cells |
| Q42048496 | RNAi therapy to the wall of arteries and veins: anatomical, physiologic, and pharmacological considerations |
| Q26747496 | ROS and Brain Gliomas: An Overview of Potential and Innovative Therapeutic Strategies |
| Q88186614 | Self-Assembled Core-Shell-Type Lipid-Polymer Hybrid Nanoparticles: Intracellular Trafficking and Relevance for Oral Absorption |
| Q47427416 | Self-assembly of peptide amphiphiles for drug delivery: the role of peptide primary and secondary structures. |
| Q38837543 | Small interfering RNA delivery by polyethylenimine-functionalised porous silicon nanoparticles. |
| Q47899284 | Synthesis of PLGA-Lipid Hybrid Nanoparticles for siRNA Delivery Using the Emulsion Method PLGA-PEG-Lipid Nanoparticles for siRNA Delivery |
Search more.